LEXINGTON, Mass., March 16, 2017 (GLOBE NEWSWIRE) -- March 16, 2017 - Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused
on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that
James Dentzer, Chief Financial Officer and Chief Administrative Officer, will present at the Oppenheimer & Co. Inc. 27th Annual
Healthcare Conference on March 21, 2017 at 2:10 p.m. Eastern Time in New York.
A corresponding webcast of the presentation can be accessed, both live and archived, by visiting:
https://www.veracast.com/webcasts/opco/healthcare2017/03110203347.cfm
The webcast will be archived shortly after the live event and will be available for 90 days through June 19, 2017. It will also
be available for 30 days on the Investor Relations section of the Curis website at www.curis.com.
About Curis, Inc.
Curis is a biotechnology company seeking to develop and commercialize innovative and effective drug candidates
for the treatment of human cancers, including its lead development candidate, CUDC-907, which is being investigated in
clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in
the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral
small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule
antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the
IRAK4 kinase, including CA-4948. Curis is currently conducting a Phase 1 trial of CA-170 in patients with advanced solid
tumors and lymphomas. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and
Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma, and are further developing Erivedge in
other diseases including idiopathic pulmonary fibrosis and myelofibrosis. For more information, visit Curis's website
at www.curis.com.
For More Information: James E. Dentzer Chief Financial Officer & Chief Administrative Officer Curis, Inc. 617-503-6597 jdentzer@curis.com Media Contact David Schull Russo Partners (212) 845-4271 david.schull@russopartnersllc.com
